Dr Reddys Labs invests Rs 565 crore in Russian subsidiary
Hyderabad: Dr. Reddy’s Laboratories Ltd has announced an investment of Rs 565.4 crore in its step-down wholly owned subsidiary, Dr. Reddy's Laboratories LLC, Russia (DRL Russia), thereby acquiring a 45.19% equity stake in the entity.
This development is in continuation of the earlier announcement dated November 5, 2024, wherein the board had approved a fund infusion of up to Rs 600 crore into DRL Russia.
The fund infused by the Company will be used for working capital requirements. The turnover of DRL Russia for FY2025 was Rs. 2,347 Crore.
Incorporated in 2003, DRL Russia is a Pharmaceutical company registered in Russian Federation distributing pharmaceutical medicines in the country. The company reported a turnover of Rs 2,347 crore for the financial year 2025, an increase from Rs 2,084 crore in FY24 and Rs 1,915 crore in FY23.
The acquisition, completed on July 25, 2025, was executed via cash consideration.
Read also: Natco Pharma appoints Yarramshetty Krishna Rao as Senior Vice President - Operations at Mekaguda
Recently, Dr. Reddy's Laboratories' has also made headlines with its plans to shake up the global weight-loss drug market with the launch of an affordable copycat version of Wegovy, the blockbuster weight-loss drug from Novo Nordisk. "U.S. and Europe will open later... (and) all the other Western markets will be open between 2029 to 2033," Israeli said a press conference to discuss the company's earnings.
Read also: Dr Reddy's Labs plans to roll out cheaper Wegovy copycat across 87 countries in 2026: CEO
Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The Company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddys major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe.
